(CercleFinance.com) – Bayer announced on Friday that the Food and Drug Administration (FDA) had accepted its request for an update regarding the labeling of Kerendia (finerenone).
The German pharmaceutical group indicates that the drug’s leaflet will now include its beneficial effects in terms of cardiovascular mortality in patients with chronic kidney disease and type 2 diabetes.
One of the most common complications of diabetes is chronic kidney disease, a life-threatening condition that is generally underdiagnosed.
It is the leading cause of end-stage kidney failure, in which patients must be on dialysis or receive a kidney transplant to stay alive.
Patients with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular disorder than patients with only DT223.
Finerenone had been approved in July 2021 under the trademark Kerendia by the Food and Drug Administration (FDA) for the treatment of chronic kidney disease and type 2 diabetes in adults.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.